Spots Global Cancer Trial Database for mrcc
Every month we try and update this database with for mrcc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma | NCT00556049 | Renal Cell Carc... Neoplasm Metast... | Gemcitabine Sunitinib | 18 Years - | Massachusetts General Hospital | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | NCT01514448 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | NCT04919122 | Metastatic Rena... | 19 Years - | Duke University | ||
| Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy | NCT03891485 | RCC Metastatic Rena... | Immunological a... | - | National Cancer Institute, Naples | |
| Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib | NCT02019576 | Clear Cell Meta... | Stereotactic ra... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | NCT00556205 | Renal Cell Carc... | Sunitinib Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma | NCT00556049 | Renal Cell Carc... Neoplasm Metast... | Gemcitabine Sunitinib | 18 Years - | Massachusetts General Hospital | |
| Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma | NCT04919122 | Metastatic Rena... | 19 Years - | Duke University | ||
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | NCT02060370 | Genitourinary C... Kidney Cancer | Sunitinib Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases | NCT03967522 | Metastatic Rena... | Cabozantinib | 18 Years - | Centre Leon Berard | |
| Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | NCT05817903 | Metastatic Rena... | Axitinib Nivolumab | 18 Years - | Consorzio Oncotech | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine. | NCT05745142 | Carcinoma, Rena... Clear-cell Meta... | Sunitinib | 18 Years - | Pfizer | |
| Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble | NCT01224288 | Renal Cell Carc... | Perfusion CT sc... | 18 Years - | M.D. Anderson Cancer Center | |
| International Multicentric Study ARON-1 | NCT05287464 | Metastatic Rena... | pembrolizumab p... | 18 Years - | Hospital of Macerata |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
